Pei regimen: a therapeutic option in small cell lung cancer? A retrospective monoinstitutional analysis of 46 consecutive cases

Corrado Boni, Maria Pagano, Licia Baldi, Roberta Gnoni, Luca Braglia, Luisa Savoldi, Francesca Zanelli, Corrado Boni, Maria Pagano, Licia Baldi, Roberta Gnoni, Luca Braglia, Luisa Savoldi, Francesca Zanelli

Abstract

Objectives: Combination chemotherapy is very active in small cell lung cancer (SCLC), although no improvement in overall survival (OS) has been done in the last 25 years, with Cisplatin-Etoposide (PE) still considered the world-wide standard, with an average median survival of about 7-8 months in patients with extended disease (ED). In 1995, a randomized trial of the Hoosier Group in 171 ED patients showed a significant advantage in overall survival in patients treated with PEI (Cisplatin, Etoposide and Ifosfamide), compared to PE. Despite that, PEI regimen has not become a commonly used regimen in SCLC.

Materials and methods: Here we present a retrospective analysis of 46 consecutive patients (30 males and 16 females) with SCLC that were treated at our Institution with PEI regimen: Cisplatin 20 mg/m2, Etoposide 75 mg/m2 and Ifosfamide 1200 mg/m2, day 1 to 4, every 3 weeks. Patients received a total of 219 cycles of chemotherapy, with a mean of 4,7 cycles per patient. Median age was 63 (range 59-70); performance status (PS) was 0 in 29 patients (63%), 1 in 13 patients (28%) and 2 in 4 patients (9%).

Results: In 19 limited disease (LD) patients partial response (PR) rate was 74%, and complete response (CR) was 16%. In 27 ED patients we observed 63% of PR and 26% of CR. Median time to progression (TTP) was 15.2 months in LD and 7.1 months in ED with median overall survival (OS) of 28.2 and 11.8 months, respectively. Toxicity was manageable, with a high dose intensity.

Conclusions: PEI regimen, in our opinion, may be a possible therapeutic option, with high activity and an acceptable toxicity profile.

Trial registration: ClinicalTrials.gov Identifier: NCT02324296 .

Institutional review board that approved the study: Institutional review board of Reggio Emilia, Azienda Ospedaliera S.Maria Nuova/IRCCS.

Figures

Figure 1
Figure 1
Overall Survival in limited and extended disease.
Figure 2
Figure 2
Time to progression in the limited and extended disease.

References

    1. American Cancer Society . Cancer facts and figures 2012. 2012.
    1. Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlahiotis A, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years : analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol. 2006;24:4539–44. doi: 10.1200/JCO.2005.04.4859.
    1. Hochstenbag MM, Twijnstra A, Wilmink JT, Woutes EF, Velde GP. Asymptomatic brain metastases (BM) in small lung cancer (SCLC): MR-imaging is useful at initial diagnosis. J Neurooncol. 2000;48:243–8. doi: 10.1023/A:1006427407281.
    1. Sorensen M, Pijls-johannesma M, Felip E, for the ESMO Guidelines Working Group Small- cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up-up. Ann Oncol. 2010;21(suppl 5):v120–5. doi: 10.1093/annonc/mdq172.
    1. Maddison P, Newsom-Davis J, Mills KR, Souhami RL. Favourable prognosis in Lambert-Eaton myasthenic syndrome and small-cell lung carcinoma. Lancet. 1999;353:117–8. doi: 10.1016/S0140-6736(05)76153-5.
    1. Maddison P, Lang B. Paraneoplastic neurological autoimmunity and serviva in small-cell lung cancer. J Neuroimmunol. 2008;201:159–62. doi: 10.1016/j.jneuroim.2008.05.024.
    1. Hanna NH., Einhorn LH. Small cell lung cancer: treatment for extensive stage disease. Malignant tumors of the lung. 2004; 287-301.
    1. Kurup A, Hanna NH. Treatment of small cell lung cancer. Crit Rev in Oncol/Hematol. 2004;52:117–26. doi: 10.1016/j.critrevonc.2004.08.005.
    1. Lad T, Piantadosi S, Thomas P, Payne D, Ruckdeschel J, Giaccone G. A prospective randomized trial to determine the benefit of surgical resection of residual disease following response of small cell lung cancer to combination chemotherapy. Chest. 1994;106:320S–3. doi: 10.1378/chest.106.6_Supplement.320S.
    1. Loehrer PJ, Sr, Rynard S, Ansari R, Songer J, Pennington K, Einhorn L. Etoposide, Ifosfamide, and cisplatin in extensive small cell lung cancer. Cancer. 1992;69:669–73. doi: 10.1002/1097-0142(19920201)69:3<669::AID-CNCR2820690312>;2-V.
    1. Rosti G, Bevilacqua G, Bidoli P, Portalone L, Santo A. e Genestreti G. Small cell lung cancer. Ann Oncol. 2006;17(Suppl.2):ii5–10.
    1. Loehrer PJ, Sr, Ansari R, Gonin R, Monaco F, Fisher W, Sandler A, et al. Cisplatin plus Etoposide with and without Ifosfamide in Extensive Small Cell Lung Cancer: a Hoosier Oncology Group Study. J Clin Oncol. 1995;13:2594–9.
    1. Johnson B, Fisher B, Fisher T, Dunlop D, Rischin D, Silberman S, et al. Phase II study of STI571 (GleevecTM) for patients with small cell lung cancer. Proc Am Soc Clin Oncol. 2002;21:293a.
    1. Dabir S, Babakoohi S, Kluge A, Morrow JJ, Kresak A, Yang M, et al. RET mutation and expression in Small-cell lung cancer. J Thorac Oncol. 2014;9(9):1316–23. doi: 10.1097/JTO.0000000000000234.
    1. Baka S, Califano R, Ferraldeschi R, Aschroft L, Thatcher N, Taylor P, et al. Phase III randomized trial of doxorubicin-based chemotherapy compared with platinum-based chemotherapy in small-cell lung cancer. Br J Cancer. 2008;99:442–7. doi: 10.1038/sj.bjc.6604480.
    1. Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A, et al. Irinotecan plus cisplatin compared qith etoposide plus cisplatin for extensive small-cell lungcancer. N Engl J Med. 2002;346:85–91. doi: 10.1056/NEJMoa003034.
    1. Lim S, Cho BC, Jung JY, Kim GM, Kim SH, Kim HR, et al. Phase II study of camtobell inj. (belotecan) in combination with cisplatin in patients with previously untreated, extensive stage small cell lung cancer. Lung Cancer. 2013;80(3):313–8. doi: 10.1016/j.lungcan.2013.02.009.
    1. Demedts I, Vermaelen K, van Meerbeeck JP. Treatment of ES-SCLC: current status and future prospects. Eur Respir J. 2010;35:202–15. doi: 10.1183/09031936.00105009.
    1. Jeremic B, Shibamoto Y, Nikolic N, Milicic B, Milisavljevic S, Dagovic A, et al. Role of radiation therapy in the combined-modality treatment of patients with extensive disease small-cell lung cancer: a randomized study. J Clin Oncol. 1999;17:2092–9.
    1. Postmus PE, Haaxma-Reiche H, Smit EF, Groen HJ, Karnicka H, Lewinski T, et al. Treatment of brain metastases of small-cell lung cancer: comparing teniposide and teniposide with whole-brain radiotherapy- a phase III study of the European Organization for the Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol. 2000;18:3400–8.
    1. Neuhaus T, Ko Y, Muller RP, Grabenbauer GG, Hedde JP, Schueller H, et al. A phase III trial of topotecan and whole brain radiation therapy for patients with CNS-metastases due to lung cancer. Br J Cancer. 2009;100:291–7. doi: 10.1038/sj.bjc.6604835.
    1. Loehrer PJ, Lauer R, Roth BJ, Williams SD, Kalasinski LA, Einhorn LH. Salvage therapy VP16 or vinblastine plus ifosfamide plus cisplatin in recurrent germ cell tumors. Ann Intern Med. 1988;109:540–6. doi: 10.7326/0003-4819-109-7-540.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅